Metacrine Inc. (NASDAQ: (MTCR) stock gained by 3.23% at last close whereas the MTCR stock price plunge by 51.96% in the pre-market trading session. Metacrine, Inc. is a clinical-stage pharmaceutical firm developing novel medicines for the treatment of liver and gastrointestinal disorders. Metacrine has created a proprietary farnesoid X receptor (FXR) platform based on a novel chemical scaffold that has shown to have an improved treatment efficacy in clinical trials.
MTCR stock’ Important Development
The company announced its results from the Phase 2a trial (NCT04773964) which is to analyze the effectiveness and acceptability of MET642 among individuals as well as its functionality. It is a 16-week long, randomized, placebo-controlled, multi-center trial. After 16 weeks of therapy, it was found to be a farnesoid X receptor (FXR) agonist in about 60 non-alcoholic steatohepatitis (NASH) patients. In addition, the company said that it will focus its clinical efforts and resources on getting MET642 into a Phase 2 study in inflammatory bowel disease (IBD) in the first half of 2022.
About MET642,
MET642 was usually well accepted, with no severe side effects reported (AEs). All of the treatment-related adverse events (AEs) were usually mild, with no obvious dose-response connection. One individual in the 3 mg cohort and one individual in the 6 mg cohort had mild-moderate itching. There were no therapy discontinuations due to pruritus. From baseline to week 16, MET642 therapy resulted in on-target mean increases in LDL-C of 5% with the 3 mg dosage and 19% with the 6 mg dose, compared to a 10% reduction with placebo.
Also,
The Company is initiating an independent assessment of early data from a nine-month animal toxicity study for MET642 that was just completed. As a consequence, extra long-term animal toxicity research may be needed to help the Phase 3 clinical trials in IBD. The independent evaluation is expected to be finished by the end of 2021, according to Metacrine.
